uniQure N.V. (NASDAQ:QURE) Given Average Rating of “Buy” by Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have received an average rating of “Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $37.4545.

QURE has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Friday, September 5th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 target price for the company in a research note on Thursday, August 14th. Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a research note on Wednesday, July 30th. Finally, Chardan Capital reiterated a “buy” rating and set a $35.00 target price on shares of uniQure in a research note on Monday, September 8th.

uniQure Price Performance

NASDAQ QURE opened at $14.84 on Tuesday. The company has a market cap of $814.27 million, a P/E ratio of -3.79 and a beta of 0.13. uniQure has a 1 year low of $4.45 and a 1 year high of $19.18. The company has a fifty day simple moving average of $15.29 and a 200 day simple moving average of $14.01. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. On average, sell-side analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling

In other news, Director Rachelle Suzanne Jacques sold 2,112 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director owned 28,346 shares in the company, valued at approximately $409,599.70. This represents a 6.93% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert Gut sold 3,336 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $48,205.20. Following the completion of the transaction, the director owned 56,879 shares of the company’s stock, valued at approximately $821,901.55. This represents a 5.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,474 shares of company stock worth $251,722. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new position in shares of uniQure in the 1st quarter valued at $2,562,000. OMERS ADMINISTRATION Corp acquired a new position in shares of uniQure in the 1st quarter valued at $152,000. Assenagon Asset Management S.A. raised its stake in shares of uniQure by 355.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock valued at $3,550,000 after buying an additional 261,323 shares in the last quarter. Northern Trust Corp increased its position in shares of uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of uniQure during the 1st quarter worth about $3,218,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.